Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024875 · ClinicalTrials.gov registry record
Neuroimaging of Parkinson's
A clinical trial of Parkinsons Disease (PD), sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07024875: Recruiting study of Parkinsons Disease (PD), sponsored by Washington University School of Medicine.
NCT07024875 is a study of Parkinsons Disease (PD) that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 120 participants, roughly in line with the 113-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024875, a study of Parkinsons Disease (PD), is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Parkinson's Disease (PD) is a neurodegenerative disorder caused by dysfunction in both subcortical structures and the cortex. The investigators recently discovered a new brain system called the Somato-Cognitive Action Network (SCAN), which could be a primary locus of dysfunction in PD. Here, the investigators will use magnetic resonance imaging techniques in PD patients to test whether SCAN is critical for PD. The investigators will determine whether SCAN is connected to PD-relevant subcortical structures, and whether PD patients exhibit altered subcortical-to-SCAN connectivity. If successful, this work will identify SCAN as a specific circuit altered in PD patients that can serve as a new target for future neuromodulatory PD therapies.
Primary Outcome
We will collect resting-state functional magnetic resonance imaging (fMRI) scans from the brains of all participants. From the fMRI scans, we will compute the functional connectivity between each of the subcortical brain structures relevant for Parkinson's disease (including substantia nigra, subthalamic nucleus, globus pallidus internus, and ventral intermediate nucleus of the thalamus) and each subdivision of primary motor cortex (Somato-Cognitive Action network and effector-specific regions c
Conditions Studied
Study Locations (1)
Missouri
- East Imaging Building - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2031-01 |
What NCT07024875 shows while recruiting
NCT07024875 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 113-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target.
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 0 interventions.
NCT07024875 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07024875 about?
NCT07024875 is a clinical study titled "Neuroimaging of Parkinson's". Parkinson's Disease (PD) is a neurodegenerative disorder caused by dysfunction in both subcortical structures and the cortex. The investigators recently discovered a new brain system called the Somato-Cognitive Action Network (SCAN), which could be a primary locus of dysfunction in PD. Here, the inv...
What is the current status of trial NCT07024875?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-08-01. Estimated completion is 2031-01.
What conditions does trial NCT07024875 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
Who is sponsoring clinical trial NCT07024875?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024875 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07024875's enrollment target sits among peer trials
120 5th of 19 higher than 15 of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
RECRUITING · Phase 3
-
Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI